As predictive biomarkers for the ICIs, tumor mutation burden (TMB) and programmed death ligand 1 (PD-L1) expression have been prospectively verified in the randomized controlled trials (RCTs) of NSCLC [6,7]. This evidence concerns the gene CD274 and neoplasm.